FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134187029> ?p ?o ?g. }

• W2134187029 endingPage "1494" @default.
• W2134187029 startingPage "1488" @default.
• W2134187029 abstract "Purpose The United Kingdom Coordinating Committee on Cancer Research anal cancer trial demonstrated the benefit of combined modality treatment (CMT) using radiotherapy (RT), infusional 5-fluorouracil, and mitomycin C over RT alone. The present study retrospectively examines the impact of the recommended 6-week treatment gap and local RT boost on long-term outcome. Methods and Materials A total of 577 patients were randomly assigned RT alone or CMT. After a 6-week gap responders received a boost using either additional external beam radiotherapy (EBRT) (15 Gy) or iridium-192 implant (25 Gy). The effect of boost, the gap between initial treatment (RT alone or CMT) and boost (Tgap), and overall treatment time (OTT) were examined for their impact on outcome. Results Among the 490 good responders, 436 (89%) patients received a boost after initial treatment. For boosted patients, the risk of anal cancer death decreased by 38% (hazard ratio [HR]: 0.62, 99% CI 0.35–1.12; p = 0.04), but there was no evidence this was mediated via a reduction in locoregional failure (LRF) (HR: 0.90, 99% CI 0.48–1.68; p = 0.66). The difference in Tgap was only 1.4 days longer for EBRT boost, compared with implant (p = 0.51). OTT was longer by 6.1 days for EBRT (p = 0.006). Tgap and OTT were not associated with LRF. Radionecrosis was reported in 8% of boosted, compared with 0% in unboosted patients (p = 0.03). Conclusions These results question the benefit of a radiotherapy boost after a 6-week gap. The higher doses of a boost may contribute more to an increased risk of late morbidity, rather than local control. The United Kingdom Coordinating Committee on Cancer Research anal cancer trial demonstrated the benefit of combined modality treatment (CMT) using radiotherapy (RT), infusional 5-fluorouracil, and mitomycin C over RT alone. The present study retrospectively examines the impact of the recommended 6-week treatment gap and local RT boost on long-term outcome. A total of 577 patients were randomly assigned RT alone or CMT. After a 6-week gap responders received a boost using either additional external beam radiotherapy (EBRT) (15 Gy) or iridium-192 implant (25 Gy). The effect of boost, the gap between initial treatment (RT alone or CMT) and boost (Tgap), and overall treatment time (OTT) were examined for their impact on outcome. Among the 490 good responders, 436 (89%) patients received a boost after initial treatment. For boosted patients, the risk of anal cancer death decreased by 38% (hazard ratio [HR]: 0.62, 99% CI 0.35–1.12; p = 0.04), but there was no evidence this was mediated via a reduction in locoregional failure (LRF) (HR: 0.90, 99% CI 0.48–1.68; p = 0.66). The difference in Tgap was only 1.4 days longer for EBRT boost, compared with implant (p = 0.51). OTT was longer by 6.1 days for EBRT (p = 0.006). Tgap and OTT were not associated with LRF. Radionecrosis was reported in 8% of boosted, compared with 0% in unboosted patients (p = 0.03). These results question the benefit of a radiotherapy boost after a 6-week gap. The higher doses of a boost may contribute more to an increased risk of late morbidity, rather than local control." @default.
• W2134187029 created "2016-06-24" @default.
• W2134187029 creator A5010709601 @default.
• W2134187029 creator A5015912702 @default.
• W2134187029 creator A5017956085 @default.
• W2134187029 creator A5024120918 @default.
• W2134187029 creator A5024289503 @default.
• W2134187029 creator A5029890517 @default.
• W2134187029 creator A5048443554 @default.
• W2134187029 creator A5050553727 @default.
• W2134187029 creator A5060082499 @default.
• W2134187029 date "2011-12-01" @default.
• W2134187029 modified "2023-09-24" @default.
• W2134187029 title "“Mind the Gap”—The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I)" @default.
• W2134187029 cites W1804130247 @default.
• W2134187029 cites W1947979503 @default.
• W2134187029 cites W1964278354 @default.
• W2134187029 cites W1972012035 @default.
• W2134187029 cites W1974234666 @default.
• W2134187029 cites W1977127004 @default.
• W2134187029 cites W1985021304 @default.
• W2134187029 cites W1989124868 @default.
• W2134187029 cites W1994934546 @default.
• W2134187029 cites W2004798450 @default.
• W2134187029 cites W2009208385 @default.
• W2134187029 cites W2016024476 @default.
• W2134187029 cites W2020355167 @default.
• W2134187029 cites W2020378886 @default.
• W2134187029 cites W2024544849 @default.
• W2134187029 cites W2025289696 @default.
• W2134187029 cites W2025708282 @default.
• W2134187029 cites W2026811255 @default.
• W2134187029 cites W2027310670 @default.
• W2134187029 cites W2031052517 @default.
• W2134187029 cites W2035478314 @default.
• W2134187029 cites W2044216592 @default.
• W2134187029 cites W2048418291 @default.
• W2134187029 cites W2051237208 @default.
• W2134187029 cites W2051941210 @default.
• W2134187029 cites W2055442814 @default.
• W2134187029 cites W2060769059 @default.
• W2134187029 cites W2062681066 @default.
• W2134187029 cites W2067126590 @default.
• W2134187029 cites W2069640589 @default.
• W2134187029 cites W2070954146 @default.
• W2134187029 cites W2083915572 @default.
• W2134187029 cites W2085848754 @default.
• W2134187029 cites W2093670250 @default.
• W2134187029 cites W2094580035 @default.
• W2134187029 cites W2105638449 @default.
• W2134187029 cites W2113901864 @default.
• W2134187029 cites W2137101661 @default.
• W2134187029 cites W2138477625 @default.
• W2134187029 cites W2148723888 @default.
• W2134187029 cites W2165649972 @default.
• W2134187029 cites W776995397 @default.
• W2134187029 doi "https://doi.org/10.1016/j.ijrobp.2010.07.1995" @default.
• W2134187029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20934265" @default.
• W2134187029 hasPublicationYear "2011" @default.
• W2134187029 type Work @default.
• W2134187029 sameAs 2134187029 @default.
• W2134187029 citedByCount "49" @default.
• W2134187029 countsByYear W21341870292012 @default.
• W2134187029 countsByYear W21341870292013 @default.
• W2134187029 countsByYear W21341870292014 @default.
• W2134187029 countsByYear W21341870292015 @default.
• W2134187029 countsByYear W21341870292016 @default.
• W2134187029 countsByYear W21341870292017 @default.
• W2134187029 countsByYear W21341870292018 @default.
• W2134187029 countsByYear W21341870292019 @default.
• W2134187029 countsByYear W21341870292020 @default.
• W2134187029 countsByYear W21341870292021 @default.
• W2134187029 countsByYear W21341870292022 @default.
• W2134187029 countsByYear W21341870292023 @default.
• W2134187029 crossrefType "journal-article" @default.
• W2134187029 hasAuthorship W2134187029A5010709601 @default.
• W2134187029 hasAuthorship W2134187029A5015912702 @default.
• W2134187029 hasAuthorship W2134187029A5017956085 @default.
• W2134187029 hasAuthorship W2134187029A5024120918 @default.
• W2134187029 hasAuthorship W2134187029A5024289503 @default.
• W2134187029 hasAuthorship W2134187029A5029890517 @default.
• W2134187029 hasAuthorship W2134187029A5048443554 @default.
• W2134187029 hasAuthorship W2134187029A5050553727 @default.
• W2134187029 hasAuthorship W2134187029A5060082499 @default.
• W2134187029 hasConcept C121608353 @default.
• W2134187029 hasConcept C126322002 @default.
• W2134187029 hasConcept C126894567 @default.
• W2134187029 hasConcept C141071460 @default.
• W2134187029 hasConcept C207103383 @default.
• W2134187029 hasConcept C2775908122 @default.
• W2134187029 hasConcept C2777416452 @default.
• W2134187029 hasConcept C2779338040 @default.
• W2134187029 hasConcept C2779840525 @default.
• W2134187029 hasConcept C2781411149 @default.
• W2134187029 hasConcept C44249647 @default.
• W2134187029 hasConcept C509974204 @default.
• W2134187029 hasConcept C71924100 @default.
• W2134187029 hasConceptScore W2134187029C121608353 @default.

• next